To bnAb or not to bnAb: defining broadly neutralising antibodies against HIV-1
SA Griffith, LE McCoy - Frontiers in immunology, 2021 - frontiersin.org
Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …
HIV vaccinology: 2021 update
HIV is a virus that remains a major health concern and results in an infection that has no
cure even after over 30 years since its discovery. As such, HIV vaccine discovery continues …
cure even after over 30 years since its discovery. As such, HIV vaccine discovery continues …
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
NN Mkhize, AEJ Yssel, H Kaldine… - PLoS …, 2023 - journals.plos.org
The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016
and 2020 showed for the first time that passively administered broadly neutralizing …
and 2020 showed for the first time that passively administered broadly neutralizing …
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
J Gorman, CSF Cheung, Z Duan, L Ou, M Wang… - Nature …, 2024 - nature.com
Lassa virus (LASV) infection is expanding outside its traditionally endemic areas in West
Africa, posing a pandemic biothreat. LASV-neutralizing antibodies, moreover, have proven …
Africa, posing a pandemic biothreat. LASV-neutralizing antibodies, moreover, have proven …
Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses
Several ebolaviruses cause outbreaks of severe disease. Vaccines and monoclonal
antibody cocktails are available to treat Ebola virus (EBOV) infections, but not Sudan virus …
antibody cocktails are available to treat Ebola virus (EBOV) infections, but not Sudan virus …
Subnanometer structure of an enveloped virus fusion complex on viral surface reveals new entry mechanisms
Paramyxoviruses—including important pathogens like parainfluenza, measles, and Nipah
viruses—use a receptor binding protein [hemagglutinin-neuraminidase (HN) for …
viruses—use a receptor binding protein [hemagglutinin-neuraminidase (HN) for …
Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth
RS Roark, H Li, WB Williams, H Chug, RD Mason… - Science, 2021 - science.org
INTRODUCTION It is widely believed that the development of an effective neutralizing
antibody–based HIV-1 vaccine will require consistent activation of multiple germline …
antibody–based HIV-1 vaccine will require consistent activation of multiple germline …
Bispecific antibody CAP256. J3LS targets V2-apex and CD4-binding sites with high breadth and potency
ABSTRACT Antibody CAP256-VRC26. 25 targets the second hypervariable region (V2) at
the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although …
the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although …
[HTML][HTML] Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design
Broadly neutralizing antibodies (bNAbs) against HIV can reduce viral transmission in
humans, but an effective therapeutic will require unusually high breadth and potency of …
humans, but an effective therapeutic will require unusually high breadth and potency of …
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South …
Introduction New HIV prevention strategies are urgently required. The discovery of broadly
neutralising antibodies (bNAbs) has provided the opportunity to evaluate passive …
neutralising antibodies (bNAbs) has provided the opportunity to evaluate passive …